CAPOX regimen

DRUG4 trials

Sponsors

Washington University School of Medicine, UNICANCER, Fudan University, Akeso

Conditions

Adenocarcinoma of the Lower RectumColorectal CancerDigestive CancerGastric / Gastroesophageal Junction AdenocarcinomaRectal Cancer

Phase 2

Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme

RecruitingNCT06475352

UNICANCERColorectal Cancer, Digestive Cancer

Start: 2025-01-20End: 2030-01-01Target: 400Updated: 2026-04-23

Phase 3

Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study

Not yet recruitingNCT07132463

Fudan UniversityRectal Cancer

Start: 2025-08-31End: 2030-12-31Target: 154Updated: 2025-08-20

Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

Not yet recruitingNCT07700979

AkesoGastric / Gastroesophageal Junction Adenocarcinoma

Start: 2026-08-20End: 2030-08-18Target: 900Updated: 2026-07-14

Unknown Phase

Non-Operative Management and Early Response Assessment in Rectal Cancer

CompletedNCT03904043

Washington University School of MedicineAdenocarcinoma of the Lower Rectum

Start: 2020-07-01End: 2026-01-25Updated: 2026-05-01

Related Papers

Dihydropyrimidine dehydrogenase phenotype-guided dose individualization of fluoropyrimidine in gastrointestinal cancers: PRODIGE100-UCGI48-FUDOSE phase II study.

2026-05-22